Discordance between insulin resistance and metabolic syndrome:: features and associated cardiovascular risk in adults with normal glucose regulation

被引:55
作者
Onat, A [1 ]
Hergenç, G
Türkmen, S
Yazici, M
Sari, I
Can, G
机构
[1] Istanbul Univ, Turkish Soc Cardiol, TR-34335 Istanbul, Turkey
[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Cardiol, TR-34335 Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Publ Hlth, TR-34335 Istanbul, Turkey
[4] Yildiz Tech Univ, Dept Biol, Istanbul, Turkey
[5] Istanbul Univ, Fac Med, Dept Cardiol, TR-34335 Istanbul, Turkey
[6] Abant Izzet Baysal Univ, Fac Med, Duzce, Turkey
[7] S Ersek Cardiovasc Surg Ctr, Istanbul, Turkey
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2006年 / 55卷 / 04期
关键词
D O I
10.1016/j.metabol.2005.10.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aims of this study were to investigate the extent of concordance between metabolic syndrome (MS) and insulin resistance (IR), the features of discordance, and the magnitude of their independent association with cardiovascular disease (CVD) risk. After exclusion of individuals with diabetes and impaired fasting glucose, the population sample of 1534 men and women, representative of Turkish adults (mean age, 52.2 years), were evaluated cross-sectionally and at a mean 2 years' follow-Lip. Metabolic syndrome was identified by criteria of the Adult Treatment Panel III, except for male waist circumference (> 94 cm). Insulin resistance was defined by the upper quartile in the sample (> 2.245) of the homeostatic model assessment (HOMA) index. Clinical fatal and nonfatal CVD existed or developed in 165 subjects. Waist circumference proved to be by far the strongest significant determinant of HOMA in both sexes, followed by triglycerides. The cohort was categorized into 4 by the presence or absence of MS and IR. Each of the latter represented 34% and 25%, but together constituted 45% of the sample, thus disclosing concordance in a third of the conditions combined. The nonconcordant IR/NoMS group was less common than the MS/NoIR group and was distinct front the latter in having significantly lower waist girth, blood pressure, apolipoprotein B and triglyceride levels, and higher high-density lipoprotein cholesterol, glucose, and insulin levels and physical activity in both sexes. When adjusted for 5 important risk factors, although the excess risk in men with MS failed to attain significance, men with IR were associated with a significant 1.9-fold CVD risk. The IR/NoMS group had a 2.2-fold (95% confidence interval, 0.97-5.11) CVD likelihood compared with the large iusulin-sensitive group, after adjustment for age, sex, log C-reactive protein, low-density lipoprotein cholesterol, smoking status, physical activity, and the 2 groups of MS with or without IR. Overlapping between MS and IR is limited in either sex, and MS/NoIR is more common than IR/NoMS. Overall, IR is more significantly associated with CVD risk than MS in men and in both sexes after adjustment for important confounders. Insulin resistance without MS tends to implicate in middle-aged and elderly Turkish men roughly a 2-fold CVD risk, corresponding to 50% excess risk per 1 SD in HOMA index, independent of MS and important covariates. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 32 条
[1]  
[Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1
[2]  
[Anonymous], 1982, CARDIOVASCULAR SURVE
[3]   Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome [J].
Cheal, KL ;
Abbasi, F ;
Lamendola, C ;
McLaughlin, T ;
Reaven, GM ;
Ford, ES .
DIABETES, 2004, 53 (05) :1195-1200
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[6]   Metabolic syndrome and insulin resistance in the TROPHY Sub-Study: Contrasting views in patients with high-normal blood pressure [J].
Egan, BM ;
Papademetriou, V ;
Wofford, M ;
Calhoun, D ;
Fernandes, J ;
Riehle, JE ;
Nesbitt, S ;
Michelson, E ;
Julius, S .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (01) :3-12
[7]   ESSENTIAL-HYPERTENSION - AN INSULIN-RESISTANT STATE [J].
FERRANNINI, E ;
HAFFNER, SM ;
STERN, MP .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 :S18-S25
[8]   A comparison of the prevalence of the metabolic syndrome using two proposed definitions [J].
Ford, ES ;
Giles, WH .
DIABETES CARE, 2003, 26 (03) :575-581
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V0018
[10]   Definition of metabolic syndrome - Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition [J].
Grundy, SM ;
Brewer, HB ;
Cleeman, JI ;
Smith, SC ;
Lenfant, C .
CIRCULATION, 2004, 109 (03) :433-438